Medovex Corporation Enters Into Medical Advisory Board Agreement With European Leading Spine Surgeon Dr. Martin Deeg

ATLANTA, GA--(Marketwired - Aug 11, 2015) - Medovex Corp. (NASDAQ: MDVX), a developer of medical technology products, today announced that the Company has entered into a medical advisory board member consulting agreement with a European leading spine surgeon Dr. Martin Deeg.

Under the terms of the agreement, Dr. Deeg will leverage his expertise, experience and relationships in the spine treatment space, specifically the Facet Joint pain area, by advising Medovex on matters related to its technology and the area of Fact Joint pain therapies. Dr. Deeg will also provide services to help introduce the Medovex's DenerveX™ System to other leading physicians and medical professionals.

Following his medical studies at Saarland University Homburg Saar, Dr. Deeg worked since 1994 as a Junior MD in orthopedic at Hospital Markgroeningen before he was appointed the position leading Senior Physician of the orthopedic department in Markgroeningen. In 2010 Dr. Deeg joined as a partner a group collaboration of orthopedic specialists, practice Mauch / Stihler / Langenbach and Partner in Stuttgart, Germany ZON (Center for Orthopaedic and Neurosurgery) one of the leading centers in Germany for treatments in the field of joint pain and spinal conditions.

Dr. Deeg's specialty in the past 20 years is in the field of surgery of the spinal column focusing in the area of artificial disc, spondylodesis / stiffening of spine, herniated disc and spinal stenosis, as well as operations in vertebral fractures / fractures by osteoprose.

Patrick Kullmann, Medovex President and COO, stated, "We look forward to working with Dr. Deeg, leveraging both his expertise and relationships as one of Europe's top spine surgeons. We expect his deep knowledge of the space will prove invaluable for our European launch of the DenerveX System. We believe that this first advisory board member along with others that will follow, coupled with our quickly established distribution strategy, will create a powerful launch preparation and sustainment for the Medovex DenerveX System in the EU." 

The Company's patented DenerveX™ System is intended to treat Facet Joint Syndrome (FJS), a condition in which the joints in the back of the spine degenerate and subsequently cause pain. Lower back pain is the second most common cause of disability in the U.S. for adults. Studies indicate that 10% of the U.S. adult population suffers from lower back pain and that 31% of lower back pain is attributed to FJS pain.

The DenerveX System consists of the DenerveX device, a single use medical device and the DenerveX Pro-40 Power generator, both designed to be less invasive with faster recovery time than current surgical treatment options. It consists of two procedures combined into one device and is expected to provide for a longer lasting treatment solution while offering potential savings to the health care system. DenerveX is not yet commercially available.

About Medovex

Medovex was formed to acquire and develop a diversified portfolio of potentially ground breaking medical technology products. Criteria for selection include those products with potential for significant improvement in the quality of patient care combined with cost effectiveness. The Company's first pipeline product, the DenerveX device, is intended to provide long lasting relief from pain associated with facet joint syndrome at significantly less cost than currently available options. To learn more about Medovex Corp., visit www.medovex.com

Safe Harbor Statement

Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company's filings with the Securities and Exchange Commission (the "SEC"), not limited to Risk Factors relating to its patent business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.